Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-004201
Filing Date
2025-02-14
Accepted
2025-02-14 17:40:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13332
2 JOINT FILING AGREEMENT ex-99-02142025_100259.htm EX-99.1 4352
  Complete submission text file 0001415889-25-004201.txt   19548
Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital Global Life Sciences Fund IV, L.P. (Filed by) CIK: 0001834150 (see all company filings)

EIN.: 981568621 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Subject) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94327 | Film No.: 25631347
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)